- $573.52m
- $454.89m
- $418.63m
Brief: Mimedx Announces Commercial Launch Of Epifix In Japan
Brief: MiMedx Announces Wound & Surgical Product Pipeline Expansion On Agreement With Turn Therapeutics
MiMedx Group Inc reports results for the quarter ended in September - Earnings Summary
Brief: Mimedx Announces Third Quarter 2022 Results
MiMedx Group Inc expected to post a loss of 8 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Abiomed, McDonald's, S&P Global
Brief: MiMedx Announces Launch Of Axiofill
Brief: Mimedx Epifix Receives Reimbursement Approval In Japan
Brief: MiMedx Group Inc - K. Todd Newton Appointed As Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately
Brief: Mimedx Announces Second Quarter 2022 Operating And Financial Results
MiMedx Group Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Mimedx Announces Formation Of Regenerative Medicine Scientific Advisory Board Comprised Of Renowned Industry And Academic Experts
Brief: MiMedx Group Engages Nordic Bioscience Clinical Development A/S To Propel Registrational Trials Of Placental Biologic Injectable For Knee Osteoarthritis
Brief: Prescience Point - Issued Open Letter To Mimedx Shareholders Commenting On Results Of Company's Annual Meeting Of Shareholders, Held On June 7, 2022
Brief: MiMedx Shareholders Vote To Approve All Proposals At The 2022 Annual Meeting
Brief: Prescience Point Capital Management Calls On Mimedx Group To Immediately Release Preliminary Voting Results Of Its Annual Meeting
Brief: Prescience Point Capital Management Says It will Will Vote Against Approval Of Executive Compensation For Mimedx Group
Brief: MiMedx Receives $4.6 Million Award From The Department Of Defense To Advance The Treatment Of Combat Casualty Wounds And Burns
Brief: Mimedx Group Inc - Co Urges Shareholders To Vote "For" Director Nominees - James L. Bierman & Phyllis Gardner, M.D. - On White Proxy Card